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96 The Journal of Thoracic and Cardiobjectives: Neurologic injury after cardiac surgery, often manifested as neurocognitive
ecline, is a common postoperative complication without clear cause. We studied acute
ariations in gene-expression profiles of patients with neurocognitive decline (NCD
roup) compared with those without neurocognitive decline (NORM group) after
ardiopulmonary bypass.
ethods: Forty-two patients undergoing coronary artery bypass grafting, valve proce-
ures, or both by using cardiopulmonary bypass were administered a validated neuro-
ognitive battery preoperatively and postoperatively at day 4. Neurocognitive decline
as defined as 1 standard deviation from baseline on 25% or greater of tasks. Whole-
lood mRNA was isolated preoperatively and at 6 hours after surgical intervention for
old-change calculation. Relative gene expression in the NCD versus the NORM group
as assessed by using Affymetrix GeneChip U133 Plus 2.0 (40,000 genes) from
RNA samples collected. Differential expression, clustering, gene ontology, and ca-
onical pathway analysis were performed. Validation of microarray gene expression
as performed with SYBR Green real-time polymerase chain reaction.
esults: Patients with neurocognitive decline (17/42 [40.5%] patients) were associated
ith a significantly different gene-expression response compared with that of healthy
atients. Compared with preoperative samples, 6-hour samples had 531 upregu-
ated and 670 downregulated genes uniquely in the NCD group compared with
214 upregulated and 558 downregulated genes uniquely in the NORM group (P
.001; lower confidence bound, 1.2). Compared with patients in the NORM
roup, patients with neurocognitive decline had significantly different gene-
xpression pathways involving inflammation (including FAS, IL2RB, and
D59), antigen presentation (including HLA-DQ1, TAP1, and TAP2), and cel-
ular adhesion (including ICAM2, ICAM3, and CAD7) among others.
onclusions: Patients with neurocognitive decline have inherently different genetic
esponses to cardiopulmonary bypass compared with those of patients without neuro-
ognitive decline Genetic variations in inflammatory, cell adhesion, and apoptotic
athways might be important contributors to the pathophysiology of neurologic injury
fter cardiopulmonary bypass and could become a target for prevention and risk
tratification.
rain injury after cardiopulmonary bypass (CPB) remains a common and
serious complication that is often misdiagnosed.1,2 Brain-protective strate-
gies include improved operative approach selection (eg, “no-touch” tech-ique for the calcified aorta), preoperative investigation (eg, carotid duplex scan-
vascular Surgery ● October 2007
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Ping), and intraoperative measures (eg, hypothermia 
PB filters). Despite these advances in surgical techni
PB, and anesthesia, central neurologic system (CNS) 
ury remains an important complication for patients. 
merican College of Cardiology/American Heart Assoc
ion guidelines for coronary artery bypass graft surg
ivide postoperative neurologic deficits into 2 categori3
ype 1 deficits (incidence of 1%-5%) include major f
eurologic events, stupor, and coma. Type 2 deficits, 
n incidence as high as 65% in some studies,4,5 describe
ore global cognitive deficits, such as deterioration in
ellectual function, memory, and confusion without e
ence of focal injury. Type 1 deficits are usually cause
dentifiable sources of cerebral hypoxia caused by intra
rative hypoperfusion or embolic phenomena. In contr
he cause of type 2 deficits is unclear and likely mu
orial, where factors such as hypoxia, time on CPB, 
ype of procedure, preoperative creatinine levels, and p
perative inflammatory response have been implicated in
athophysiology.6
The remarkably high incidence of type 2 brain in
measured at 1 week postoperatively), usually improves 
ecreases to around 10% to 30% at 1 year. Interesti
ewman and colleagues7 have reported that the occurren
f early neurocognitive decline (NCD) in cardiac surg
atients is predictive of long-term decline. One of the
ons why the incidence of type 2 CNS injury remai
igh in spite of recent advances might be a fundamenta
n the understanding of the pathophysiology of this typ
njury.1,6
The inflammatory response and associated oxidati
tress have been implicated in the development of pos
rative CPB-associated complications.8-12 These are trig-
ered by the activation of blood components on the arti
urface of the extracorporeal circuit, such as the activa
f leukocytes, complement, expression of adhesion mo
Abbreviations and Acronyms
BP  biologic process
CNS  central neurologic system
CPB  cardiopulmonary bypass
FC  fold change
GO  gene ontology
LCB  lower confidence bound
NCD  neurocognitive decline
NORM without neurocognitive decline
PRE  preoperatively after induction of anesthesia
and before skin incision
SD  standard deviation
6h  6 hours postoperatively in the cardiovascular
intensive care unitules, cytokine release, and an increase in reactive oxygenL
The Journal of Thoracicy
-
,
,
-
o
k
f
l
pecies, such as peroxides, that mediate oxidative stres
s increasingly recognized that there exists a certain am
f variability in the magnitude and duration of respon
PB between patients, which has been implicated in 
ient and permanent end-organ damage. Our group, am
thers, has reported on the strong association between N
nd the magnitude of the inflammatory response a
PB.13,14
Transcriptional profiling with high-density microarra
rovides unique data about disease mechanisms, drug 
ponses, regulatory pathways, and gene function by c
aring the level of mRNA transcribed in cells in a 
athologic state versus a control. This technology can
entially elucidate complex pathophysiologic associatio
echanisms directly at the gene-expression level. T
resent study was conducted to examine the difference
ene-expression profiles of patients who have NCD a
ardiac surgery compared with those who do not have
omplication in an effort to improve our understandin
ype 2 brain injury and provide perioperative strate
imed at prevention and treatment.
aterials and Methods
atient Enrollment
e carried out a single-institution, prospective cohort study 
as approved by the Beth Israel Deaconess Medical Center 
utional Review Board/Committee on Clinical Investigatio
orty-three patients scheduled for elective or urgent primary 
nary artery bypass grafting, valvular surgery (aortic or mitra
 combination of the 2 with CPB provided informed w
onsent and were enrolled. Exclusion criteria included the fol
ng: patients undergoing aortic arch/root procedures and those 
alcified aorta, recent stroke, severe preoperative neurologic 
cits, known high-grade carotid stenosis, advanced hepatic disease
cirrhosis), and chronic renal failure (serum creatinine, 2.0 mg/
L). Patients who were unable to complete the baseline neuropsy-
hological battery because of severe cognitive impairment, psy-
hiatric disease, substance abuse, blindness, or poor English were
lso excluded. One patient was excluded from the analysis because
f inability to complete the neuropsychological assessment before
ischarge. Thus 42 patients were included in the analysis.
nesthetic and Surgical Techniques
he conventional operative approach at our institution was fol-
owed, including induction of general anesthesia, invasive moni-
oring, midline sternotomy, and systemic heparinization. CPB was
nitiated through cannulation of the right atrium and ascending
orta with a nonpulsatile system, membrane oxygenator, and
0-m arterial filter. Crystalloid pump prime was used. For all
atients, mild hypothermic CPB (minimum temperature, 32°C-
4°C) with intermittent cold blood hyperkalemic (25 mmol/L)
ardioplegia was used. Serum glucose levels were monitored,
nd we attempted to maintain a value of less than 130 mg/dL by
eans of intermittent intravenous insulin injections or insulin
nfusion. During CPB, pump blood flow was maintained at 2 to 2.4
· min1 · m2 body surface area. Arterial partial oxygen
and Cardiovascular Surgery ● Volume 134, Number 4 997
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CSPressure was maintained at between 150 and 250 mm Hg
lpha-stat pH monitoring was used. Mean blood pressure 
aintained between 50 and 90 mm Hg by using convent
asoactive medications.
eurocognitive Assessment
atients underwent neurocognitive testing with a battery
valuations preoperatively (1-10 days before surgical interv
ion) and postoperatively before discharge at postoperative 
, as well as at 3 months. Before baseline neurocogn
ssessment, all patients underwent a depression assessment
sing the Geriatric Depression Scale (positive if score  9 of
5). All evaluations were carried out by trained and dedi
sychometricians who were blinded to serologic testing. 
attery was chosen to be consistent with the “Statemen
onsensus on neurobehavioral outcomes after cardiac s
ery”15 and consisted of 8 validated assessments cover
emory, executive function, attention, language, and glo
ognition.
From the Hopkins Verbal Learning Test, a validated 12-
erbal learning, retention, and recall measure, we assessed
umber of items learned, the number of items recalled af
0-minute delay divided by the maximum number of i
earned, and the number of items correctly identified from a
onfrontational naming was measured with the Boston Nam
est.16 Time to complete Trailmaking A and B, a measur
hifting attention abilities, was recorded. Digit span forw
nd backward of the Revised Wechsler Adult Intelligence S
s a measure of working memory and sustained attention
uiring participants to hold and manipulate information. F
ncy tasks are measures that assess language and knowl
torage patterns by requiring the patient to spontaneously 
rate words in a category (semantic) or beginning with a
ific letter (phonemic). Performance on the Weschler Tes
dult Reading, an irregular-word reading task, was used 
easure of premorbid intelligence. The Stroop Color-W
nterference test assesses executive function, and we recor
he number of correct responses. The visual search and a
est requires visuospatial abilities and executive function.
Following the “Consensus statement on neurobehavio
hanges following cardiac surgery” guidelines, we defined c
itive decline as a 1-standard-deviation (SD) decline f
aseline on 25% of the tasks (2/8 measures).17 The SD wa
erived by performing the cognitive battery in a similar p
ation undergoing cardiac surgery.18
lood Sampling and Microarray Processing
or each of the 42 patients, blood samples were collected 
he central venous line preoperatively after induction of a
hesia and before skin incision (PRE), as well as 6 
ostoperatively in the cardiovascular intensive care unit (
lood samples were collected into PAXgene tubes (QIAG
nc, Valencia, Calif) for immediate mRNA stabilization 
xtraction, as per the manufacturer’s recommendation. Tr
criptional profiles of samples were probed by using Affym
G (Affymetrix Inc, Santa Clara, Calif) U133 Plus 2.0 chip
 total of 84 chips. Total RNA extraction and purifica
DNA synthesis, in vitro transcription reaction for production i
98 The Journal of Thoracic and Cardiovascular Surgery ● Octoa
.
-
s
r
 f biotin-labeled cRNA, hybridization of cRNA with Affym
eneChips, and scanning of arrays were done according to previ
escribed protocols.19 All arrays went through stringent quality c-
rol assessment with regard to 3=/5= ratios (by using glyceraldehyde
-phosphate dehydrogenase and -actin probes), percentage o
resent calls, and array outlier call percentage within 2 SDs of 
ean. All scanned array images passed the quality controls
ere analyzed by using dChip,20 which has been shown to be m
obust than Affymetrix software Microarray Analysis Suite 5.
ignal calculation for about 60% of genes.21 In the dChip analys
 smoothing spline normalization method was applied before
aining model-based gene-expression indices, also known as sig
alues. There were no outliers identified by using dChip,
herefore all samples were carried on for subsequent analysis
nsupervised and Differential Expression Analysis
 hierarchic clustering technique was used to construct
nweighted pair group method with arithmetic-mean tree 
sing the Pearson correlation as the metric of similarity. W
omparing 2 groups of samples to identify genes enriched
iven group, we used the lower confidence bound (LCB) o
old change (FC) between the 2 groups (6H vs PRE) a
utoff criteria. If 90% LCB of FC between the 2 group
reater than 1.2, the corresponding gene was considered t
ifferentially expressed. LCB is a stringent estimate of the
nd has been shown to be the better ranking statistic.20 Re-
ently, dChip’s LCB method for assessing differentially 
ressed genes has been shown to be superior to other comm
sed approaches, such as Microarray Analysis Suite 5.0 –
obust Multiarray Average– based methods.22,23 By using cus-
om arrays and quantitative reverse transcriptase real-time p
erase chain reaction, it has been suggested that Affym
hips might underestimate differences in gene expression17
ased on this work and others,24 a criterion of selecting gen
hat have an LCB of greater than 1.2 most likely correspon
enes with an “actual” FC of at least 3 in gene expressi
ene Ontology Analysis
nce gene lists that are differentially expressed between vari-
us groups have been calculated, we identified the gene ontol-
gy (GO) categories for each of these input gene sets.25 This
pproach suggests biologic areas that warrant further study by
iscovering GO categories that exist in significant abundance in
he input gene list by using hypergeometric distribution (P 
05). For each category, the actual number represents the num-
er of upregulated genes in that category. The expected number
s a calculated value obtained by determining the ratio of genes
n the particular category to the total number of genes and
ultiplying by the number of genes found to be upregulated.
he expected number is therefore the number of genes pre-
icted to be upregulated if the genes were distributed randomly
mong categories.
athway Analysis
athway analyses of genes were performed by using the Inge-
uity Pathways Knowledge Base (Redwood City, Calif), which
s a manually curated database of previously published findings
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Pn mammalian biology from the public literature. We used
etwork analysis, using the knowledge base to identify i
ctions of input genes within the context of known bio
athways. To this end, we investigated the established pathw
n the knowledge base.
eal-time Polymerase Chain Reaction
fter total RNA extraction, concentrations were determined
eans of spectrophotometry; each sample yielded a minim
f 10  g of total RNA with an A260/A280 ratio ran
etween 1.7 and 1.9. Integrity of total RNA was confirme
eans of Agarose gel electrophoresis, and only samples w
atio of 2:1 28S/18S were used for analysis.
The quantitative real-time SYBR Green reaction was 
ormed in duplicate, according to recommended protocols 
ided by the TaqMan ABI 7700 (Applied Biosystems, Foster 
alif). RT2 polymerase chain reaction primers for the hu
enes analyzed were obtained commercially available (Superar
ioscience Corp, Frederick, Md). Primers for the 3= ends of gene
ere used for microarray validation, including the downregul
enes HLA-DQA1, FBP2, and PYGB and the upregulated gene
YCL2, IFIH1, and TFAP2B.
linical Data Analysis
linical data were expressed as means  SD. Following th
Statement of consensus on assessment of neurobehavio
utcomes after cardiac surgery” guidelines,15 we defined cog-
itive decline through a dichotomous variable as a 1-SD
rease from baseline on 25% of the tasks (2/8 measures). T 2
est or Fisher exact test was used to compare proportions
ABLE 1. Baseline patient characteristics for the entire c
roup) neurocognitive deficits after cardiopulmonary bypa
haracteristic Cohort (42 patie
reoperative data
Age (y) 66.7 10.5
Sex (% male) 85.7 (36/42
Race (% white) 88.1 (37/42
Hypertension (% of cohort) 76.2 (32/42
Hypercholesterolemia (% of cohort) 61.9 (26/42
Diabetes mellitus (% of cohort) 76.2 (32/42
Creatinine (mg/dL) 40.5 (17/42
Leukocytes (103 cells/L) 1.31 1.4
Hematocrit (% of cohort) 7.6 2.2
Hemoglobin (g/dL) 35.8 4.3
perative data
Procedure (% CABG) 76.2 (32/42
CPB time (min) 85.3 31.2
Crossclamp time (min) 62.3 28.7
Aprotinin (% of cohort) 33.3 (14/42
Aminocaproic acid (Amicar; % of cohort) 66.7 (28/42
Cardiotomy suction (% of cohort) 61.9 (26/42
Cell saver (% of cohort) 42.9 (18/42
CD, Neurocognitive decline; NORM, without neurocognitive decline; CABhe Student t test was used to compare continuous variables. o
The Journal of Thoracicoftware packages used were GraphPad Prism 4 (GraphPad,
an Diego, Calif) and SPSS (SPSS 11.5 for Windows; SPSS,
nc, Chicago, Ill).
esults
atient Characteristics
rom 68 patients who were eligible for the study and
pproached for enrollment/consent during the study pe-
iod, 24 refused enrollment. One patient was approached
ut was subsequently not consented because of delirium.
orty-three patients provided informed written consent
nd were enrolled. One patient was subsequently ex-
luded from the analysis because of refusal to complete
europsychologic assessment before discharge (volun-
ary withdrawal). Thus 42 patients were included in the
nalysis.
Early NCD rate at postoperative day 4 was 40.5% (17/42).
lmost all patients returned to baseline cognitive function at
he 3-month time point because the NCD rate was 2.5% (1/42).
aseline patient characteristics and key perioperative data
ere similar between patients who had NCD (NCD group) at
ostoperative day 4 compared with those who did not have
CD (NORM group) and are summarized in Table 1. Pa
nderwent similar intraoperative courses with respect to CPB
echnique, temperature, anesthesia, and perioperative monitor-
ng. No focal neurologic deficits or stroke occurred in enrolled
atients. Similarly, no differences were observed in other post-
t, as well as those with (NCD group) and without (NORM
ean  standard deviation)
NCD group (17/42) NORM group (25/42) P value
68.2  10.7 65.7 10.5 .45
82.4 (14/17) 72.0 (22/25) .71
94.0 (16/17) 84.0 (21/25) .33
82.4 (14/17) 72.0 (18/25) .45
58.8 (10/17) 64.0 (16/25) .74
82.4 (14/17) 72 (18/25) .45
35.3 (6/17) 44.0 (11/25) .58
1.68  2.2 1.07 0.4 .18
7.5  2.0 7.6 2.3 .86
36.1  4.7 35.6 4.2 .73
82.4 (14/17) 72.0 (18/25) .45
91.2  26.3 81.3 33.7 .15
65.9  23.8 59.8 31.5 .24
35.3 (6/17) 32.0 (8/25) .42
64.7 (11/17) 68.0 (17/25) .42
58.8 (10/17) 64.0 (16/25) .37
35.3 (6/17) 32.0 (8/25) .37
ronary artery bypass grafting; CPB, cardiopulmonary bypass.ohor
ss (m
nts)
)
)
)
)
)
)
)
)
)
)
)perative complications for patients in the NCD group com-
and Cardiovascular Surgery ● Volume 134, Number 4 999
p gativ
t
D th
T
U
a
p
l
g
p
(
p
H
d
v
l
w
l
w
w
6
w
2
t
v
r
d
u ure
1 es
a bles
E 3 Õ
Cardiopulmonary Support and Physiology Ramlawi et al
1
CSPared with those in the NORM group. All patients had ne
est results for depression preoperatively.
ifferential Gene Expression in NCD Compared Wi
hat in NORM Patients
sing the described microarray GeneChip, we generated
nearly comprehensive database of gene expression in
atients with and without NCD after CPB. A complete
ist of gene expression, upregulated and downregulated
ene lists, and functional and correlation analyses are
rovided in the online supplementary data Web site
http://www.bidmcgenomics.org/NCD/index.html).
Cluster analysis of complete array expression values
roduced expression similarities across the samples.
ierarchic clustering of all samples demonstrated a clear
istinction based on the sample collection time: PRE
ersus 6h. In the NCD group 6490 genes were upregu- a
000 The Journal of Thoracic and Cardiovascular Surgery ● Octeated and 1147 genes were downregulated at 6h compared
ith PRE. In the NORM group 8173 genes were upregu-
ated and 1035 genes were downregulated at 6h compared
ith PRE. When these gene lists were compared,
e found that 5959 genes were commonly upregulated at
h versus PRE regardless of the NCD status, 531 genes
ere uniquely upregulated in NCD group patients, and
214 genes were uniquely upregulated in NORM pa-
ients. Among the genes that were downregulated at 6h
ersus PRE, 477 genes were commonly downregulated
egardless of the NCD status, 670 genes were uniquely
ownregulated in patients with NCD, and 558 genes were
niquely downregulated in patients without NCD (Fig
). Selected upregulated and downregulated gen
re presented for NCD group patients only (Ta
1 and E2) and NORM patients only (Tables E
Figure 1. Genes that were differen-
tially expressed after cardiopulmonary
bypass (CPB) in patients with (NCD
group) and without (NORM group) neu-
rocognitive decline: A, upregulated
genes; B, downregulated genes. 6H,
Six hours postoperatively in the car-
diovascular intensive care unit; PRE,
preoperatively after induction of anes-
thesia and before skin incision.nd E4).
ober 2007
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Pene Ontology of Pathways Differentially Expressed
n NCD Patients
s expected, unsupervised analysis of gene-expression d
id not reveal an overarching separation based on N
tatus and implied that the expression difference becaus
CD status is more subtle and requires supervised ana
f expression data. Genes that were uniquely upregulate
ownregulated at 6h compared with PRE in either g
NCD or NORM) were classified into GO groups base
heir biologic process (BP). For pathway analysis, we 
btained genes that are uniquely upregulated or downre
ated between the 6h and PRE time points with respe
CD status. To this end, we combined the 531 and
enes (from Figure 1) that were specifically changed
atients with NCD (up or down) to obtain genes tha
ifferentially expressed uniquely in patients with NC
imilarly, we combined the 2214 and 558 genes (
igure 1) that were specifically changed in NORM pat
o obtain genes that are differentially expressed uniquel
ORM patients. We then investigated the expression
hese 2 gene sets on the established pathways in Inge
athways Knowledge Base, also known as “canon
athways.”
Table 2 summarizes selected categories of genes 
ontained significantly more than expected numbers 
enes for a particular pathway when comparing the N
nd NORM groups (P  .05). Among the genes that we
ownregulated uniquely in the NCD group compared w
he NORM group, GO BP categories of pathways that 
ignificant included immune response, antigen presentatio
ntigen processing, humoral immune response, T-cell a
ation, and cell-cell adhesion (Figure 2). Genetic pathw
ABLE 2. Gene ontology biologic process pathways that
reoperatively in patients with neurocognitive decline com
ene regulation (6h vs PRE) Patient group Biologic process no
own NCD present 6955
19884
19886
6959
7166
42110
NCD absent 6952
7218
p NCD present 7596
6917
NCD absent 45454
6950
6916
6635
h, Six hours postoperatively; PRE, preoperatively; NCD, neurocognitive dhat were uniquely downregulated in NORM patients in-i
The Journal of Thoracico
0
e
luded defense response and neuropeptide signaling pa
ay categories. When upregulated genes in patients w
CD were analyzed, we identified blood coagulation a
mportant GO BP category that was represented wit
ignificantly greater number of genes than the NO
roup. Similarly, cell redox homeostasis, response to str
ntiapoptosis, and fatty acid -oxidation were identified a
elected GO BP categories that were in significant a
ance among the genes that were upregulated in NO
atients. A complete list of GO BP categories that
epresented significantly in genes that were uniquely 
egulated or downregulated depending on their NCD st
an be found in online supplementary data (http://w
idmcgenomics.org/NCD).
In Figure 3 we show the results of the aforementi
nalysis on the antigen presentation pathway. Colo
odes represent genes that exist in the input gene 
here red denotes upregulation at 6h compared with 
nd green denotes downregulation at 6h compared w
RE in the respective gene lists. We observe a p
ctivation of the pathway for both gene lists, where the
irection of this activation is opposite in the NORM versus
CD groups. Genes that were changed specifically in pa-
ients with NCD show downregulation at 6h compared with
RE, as reflected on this pathway.
Microarray expression validation with RT2–polymerase
hain reaction was consistent with GeneChip data for all 6
ene primers studied, as summarized in Figure 4.
iscussion
xtensive research has been focused on clinical and
ifferentially expressed at 6 hours postoperatively versus
ed with patients without neurocognitive decline
Gene ontology pathway Genes observed P value
mmune response 32 .000008
ntigen presentation, exogenous 6 .000026
ntigen processing through MHC II 6 .00003
umoral immune response 5 .002033
ell-surface receptor transduction 14 .003332
-cell activation 4 .004954
ell-cell adhesion 7 .006279
efense response 6 .03404
europeptide signaling pathway 4 .046216
lood coagulation 7 .001267
nduction of apoptosis 6 .048673
ell redox homeostasis 5 .003162
esponse to stress 19 .007486
ntiapoptosis 20 .010814
atty acid -oxidation 4 .039869
; MHC II, major histocompatibility complex II.are d
par
.
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CSPommon cardiac surgical complication. Several grou
ave shown significant associations between factors su
s microemboli, perioperative temperature, anesthesi
nd other neuroprotective strategies that clearly affect 
athophysiology of NCD after cardiac surgery.26-30 As a
esult of this body of data, we have a clearer unders
ng of the possible mechanisms that contribute to 
evelopment of neurologic dysfunction after cardiac s
ery. Most importantly, we have learned that it is l
 multifactorial process that is difficult to prevent or 
ecause this extensive research has failed to translate 
mprovements in NCD occurrence after cardiac surge
n fact, the incidence of NCD after CPB is arguab
igh today as it was a decade ago. Why is this?
We believe that this study sheds some light on this issue
ecause it highlights the important inherent differences that
xist at the genetic level between patients who have type 2
rain injury after CPB, as manifested by NCD, and those
ho do not have this complication. By using genome-wide
icroarray gene-expression methods, we identified several
enetic pathways that were differentially regulated in pa-
ients with NCD with statistical significance. For example,
atients in the NCD group had significant downregulation
f pathways involving inflammation, antigen presentation,
-cell activation, and intercellular adhesion. Such pathways
re critical components of the patients’ response to the CPB
nsult. We cannot, however, determine exactly from this
tudy how such downregulation affects the complex cascade
f intracellular and extracellular events that eventually cul-
inate in NCD because their clinical significance might not
e entirely clear. It is possible that downregulation of the
ell-cell adhesion pathway leads to increased vascular per-
eability and increased brain edema in these patients. Sim-
larly, it might be that upregulation of the blood coagulation
athway in patient with NCD leads to increased micro-
hrombotic events, which lead to decreased perfusion to the
ippocampus and cerebrum. Also, upregulation of genes
nvolved in the response-to-stress pathway in NORM pa-
ients might have had a protective effect against brain
njury.
Our data point to the fact that CPB does not cause an
ndiscriminate variation in gene expression in all pa-
ients. Rather, depending on the patient, CPB induces a
istinct pattern of changes in specific pathways that are
ighly associated with NCD postoperatively. These data
nd subsequent conclusions were based on patients with
imilar baseline clinical and perioperative characteristics
nd then subjected to stringent bioinformatics analysis
nd validation by using conventional techniques. Sample
ize is a clear limitation to this study because some of the
aseline clinical parameters between the 2 groups might
ave reached significance if the sample size was larger.
his study, however, demonstrates these strong associa- s
002 The Journal of Thoracic and Cardiovascular Surgery ● Oct-
t
s
ions despite the sample size, which attests to the strength
f relationships between particular pathway regulation
nd NCD status.
Another important observation from this study is that
nflammatory and immunologic responses to CPB are in-
erently different at the genetic level in patients, depending
n NCD status. This corroborates previous work by our
roup that revealed proteomic differences in which patients
ith NCD after CPB had significantly higher serologic
nflammatory indices compared with those of patients with-
ut NCD after CPB.14 This link to the patients’ different
nflammatory response to brain injury is not isolated to the
ardiac surgical sphere. During the inflammatory response,
eripheral cytokines have been found to penetrate the
lood-brain barrier directly through active transport mech-
nisms or indirectly through vagal nerve stimulation.31 It
as been shown that inflammatory mechanisms within the
NS contribute to cognitive impairment through cytokine-
ediated interactions between neurons and glial cells (eg,
eurodegenerative diseases, such as Alzheimer’s and vas-
ular dementia).31 Also, this response promotes membra
ermeability and edema, contributing to end-organ dysfunc-
ion and possible neurologic injury observed in many
atients.
In a recent study it was found that long-term cognitive
utcomes after cardiac surgery are no different in patients
ndergoing conventional coronary revascularization with
PB compared with those in medically treated cardiac
atients as control subjects.32 Such important studies, a
ell as this one (NCD rate at 3 months decreases to 2.5%)
nderscore the increasing body of evidence that such type 2
eurologic deficits are transient rather than long term. Po-
entially, in genetically susceptible patients the cognitive
eficits are manifested during times of perioperative inflam-
atory stress and subsequently resolve as the inflammatory
esponse subsides.
Our data certainly point to an inherently different re-
ponse to CPB at the genetic level in patients who have
CD postoperatively. Certainly, such findings also point to
bigger question: Do these patients, or other cohorts, react
ifferently to different insults, and thus are they more prone
o increased complications? Such studies might prove to be
eneficial in improving preoperative risk assessment and
lucidating the pathophysiology of other surgical complica-
ions. We hope that further study of differentially expressed
enetic pathways, in addition to established knowledge on
linical risk factors and perioperative factors, will translate
nto better understanding of NCD pathophysiology after
PB. In the short-term, however, it might be that such data
ould form the basis for a database of genetic information
hat could prove beneficial gene-based risk-stratification
trategies.
ober 2007
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CS
PFigure 2. Heat maps with hierarchic clustering of genes in pathways showing differential expression in patients
with neurocognitive decline (NCD) versus those without neurocognitive decline (NORM group). The cell-cell
adhesion (A) and immune response (B) pathways were both downregulated postoperatively uniquely in the NCD
group. The blood coagulation pathway (C) was upregulated uniquely in the NCD group. Also, the response-to-stress
pathway (D) was uniquely upregulated in the NORM group.The Journal of Thoracic and Cardiovascular Surgery ● Volume 134, Number 4 1003
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1
CSPFigure 3. Significantly different expression of genes involved in the antigen presentation pathway in patients with
neurocognitive decline (NCD; A) in contract to patients without neurocognitive decline (NORM; B). Red, Upregu-
lation; green, downregulation.004 The Journal of Thoracic and Cardiovascular Surgery ● October 2007
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CSPABLE E1. Selected genes exhibiting significant upregulation at 6 hours postoperatively compared with preoperatively
niquely in patients with neurocognitive deficit
ccession Gene ID Gene FC LCB
M_030937 81669 Cyclin L2 5.06 1.44
M_003221 7021 Transcription factor AP-2  4.31 1.75
V658684 4616 Growth arrest and DNA damage–inducible,  3.18 1.76
I653117 966 CD59 antigen p18–20 (antigen identified by monoclonal antibodies) 2.96 1.6
C029442 5797 Protein tyrosine phosphatase, receptor type, M 2.9 1.39
M_000570 2214 Fc fragment of IgG, low-affinity IIIa, receptor (CD16a) 2.59 1.23
25975 5062 p21 (CDKN1A)–activated kinase 2 2.55 1.66
K074045 85302 Fas (TNFRSF6) binding factor 1 2.54 1.24
M_004486 2801 Golgl autoantigen, golgin subfamily a, 2 2.52 1.42
80802 2649 Nuclear receptor subfamily 6, group A, member 1 2.48 1.33
F196874 64163 Interferon-responsive gene 15 2.37 1.38
M_000250 4353 Myeloperoxidase 2.27 1.37
M_002686 5409 Phenylethanolamine N-methyltransferase 2.24 1.57
F311866 5738 Prostaglandin F2 receptor–negative regulator 2.16 1.22
M_145046 125972 Calreticulla 3 2.12 1.2
B005043 8651 Suppressor of cytokine signaling 1 2.1 1.23
F589679 9255 Inducible cytokine subfamily E, member 1 (endothelial monocyte
activating)
2.08 1.39
F221850 2181 Acyl-CoA synthetase long-chain family member 3 2.07 1.45
M_016185 51155 Hematologic and neurologic expressed 1 2.05 1.4
39657 5608 Mitogen-activated protein kinase kinase 6 2 1.36
M_004620 7189 TNF receptor–associated factor 6 1.94 1.28
L577322 6383 Ssyndecan 2 (heparan sulfate proteoglycan 1, cell surface–associated,
fibroglycan)
1.9 1.35
F251120 27178 Interleukin 1 family, member 7 () 1.88 1.27
I126453 170712 Cytochrome c oxidase subunit VIIb2 1.87 1.37
V649018 4179 Membrane cofactor protein (CD46, trophoblast-lymphocyte cross-
reactive antigen)
1.75 1.2
38169 80271 Inositol 1,4,5-trisphosphate 3-kinase C 1.74 1.32
I821602 3480 Insulin-like growth factor 1 receptor 1.73 1.27
72082 22918 Complement component 1, subcomponent, receptor 1 1.71 1.24
81695 3687 Integrin X (antigen CD11C (p150)  polypeptide) 1.7 1.24
M_005391 5165 Pyruvate dehydrogenase kinase, isoenzyme 3 1.67 1.29
or a complete list, please refer to the Web site referenced in the text.
C, Fold change; LCB, lower confidence bound; TNF, tumor necrosis factor; Acyl-CoA, acyl-coenzyme A.005.e1 The Journal of Thoracic and Cardiovascular Surgery ● October 2007
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Ramlawi et al Cardiopulmonary Support and PhysiologyABLE E2. Selected genes exhibiting significant downregulation at 6 hours postoperatively compared with preoperatively
niquely in patients with neurocognitive deficit
ccession Gene ID Gene FG LCB
M_002589 5099 BH-protocadherin (brain-heart) 4.18 2.23
M_000954 5730 Prostaglandin D2 synthase 21 kd (brain) 3.41 1.47
M_004936 1030 Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) 2.62 1.54
M_002122 3117 Major histocompatibility complex, class II, DQ 1 2.58 1.2
M_000878 3560 Interleukin 2 receptor,  2.54 1.48
M_006137 924 CD7 antigen (p41) 2.54 1.43
M_005816 10225 CD96 antigen 2.21 1.41
47924 920 CD4 antigen (p55) 2.2 1.62
M_002185 3575 Interleukin 7 receptor 2.2 1.58
I797836 921 CD5 antigen (p56–62) 2.17 1.56
M_000839 2912 Glutamate receptor, metabotropic 2 2.13 1.25
M_014349 80833 Apolipoprotein L, 3 2.06 1.42
M_022819 64600 Phospbollpase A2, group IIF 2.06 1.31
A035414 9881 Lupus brain antigen 1 2.05 1.46
76775 3108 Major histocompatibility complex, class II, DM  2 1.39
28590 972 CD74 antigen (invariant polypeptide of MHC-II antigen associated) 1.98 1.25
F005487 3128 Major histocompatibility complex, class II, DR6 1.93 1.39
M_016579 51293 CD320 antigen 1.93 1.29
B002328 23523 Calcineurin-binding protein 1 1.92 1.45
C015186 5156 Platelet-derived growth factor receptor,  polypeptide 1.91 1.53
M_003790 8718 Tumor necrosis factor receptor superfamily, member 25 1.91 1.29
I084226 9214 Fas apoptotic inhibitory molecule 3 1.91 1.2●
M_172139 282616 Interleukin 28A (interferon, 2) 1.91 1.23
27487 3113 Major histocompatibility complex, class II, DP 1 1.84 1.3
M_000206 3561 Interleukin 2 receptor,  1.83 1.42
F269133 50615 Interleukin 21 receptor 1.8 1.32
I829170 23015 Golgi antoantigen, golgin subfamily a, BA 1.76 1.24
C001830 7041 Transforming growth factor 1 induced transcript 1 1.72 1.28
J297586 3123 Major histocompatibility complex, class II, DR1 1.72 1.21
A126728 3384 Intercellular adhesion molecule 2 1.71 1.36
M_005601 4818 Natural killer cell group 7 sequence 1.66 1.21
M_004361 1005 Cadherin 7, type 2 1.65 1.26
M_002346 4061 Lymphocyte antigen 6 complex, locus E 1.63 1.28
I358867 348 Apolipoprotein E 1.51 1.24
36759 171558 Pre-T-cell antigen receptor  1.51 1.23
M_001571 3661 Interferon regulatory factor 3 1.51 1.2
G236280 942 CD86 antigen (CD28 antigen ligand 2, B7-2 antigen) 1.43 1.22
M_031440 83597 Transmembrane protein 7 1.39 1.22
or a complete list, please refer to the Web site referenced in the text.
C, Fold change; LCB, lower confidence bound; MHC-II, major histocompatibility complex II.
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CSPABLE E3. Selected genes exhibiting significant upregulation at 6 hours postoperatively compared with preoperatively
niquely in patients without neurocognitive deficit
ccession Gene ID Gene FC LCB
M_022168 64135 Interferon induced with helicase C domain 1 5.89 2.77
F204231 23015 Golgi autoantigen, golgin subfamily a, 8A 3.62 2.44
95035 948 CD36 antigen (thrombospondin receptor) 3.5 2.34
W300598 160760 T-cell activation protein phosphatase 2C 2.98 1.81
M_013374 10015 Programmed cell death 6–interacting protein 2.79 1.95
05812 3480 Insulin-like growth factor 1 receptor 2.79 1.84
I275597 2909 Glucocorticoid receptor DNA binding factor 1 2.36 1.59
W207699 29767 Tropomodulin 2 (neuronal) 2.3 1.4
I185160 27250 Programmed cell death 4 2.28 1.64
I657064 387837 Macrophage antigen h 2.26 1.44
A742237 7916 HLA-B–associated transcript 2 2.25 1.64
16276 3119 Major histocompatibility complex, class II, DQ1 2.24 1.23
W117229 22926 Activating transcription factor 6 2.23 1.58
E217880 3575 Interleukin 7 receptor 2.21 1.39
W411030 374868 ATPase, class II, type 9B 2.09 1.63
M_004763 9270 Integrin 1 binding protein 1 2.04 1.21
U153405 835 Caspase 2, apoptosis-related cysteine peptidase 2.02 1.51
G230614 961 CD47 antigen (Rh-related antigen, integrin) 2 1.35
M_001558 3587 Interleukin 10 receptor,  1.97 1.47
M_002198 3659 Interferon regulatory factor 1 1.97 1.41
M_000591 929 CD14 antigen 1.95 1.51
U151801 708 Complement component 1, q binding protein 1.94 1.38
A700015 965 CD58 antigen (lymphocyte function antigen 3) 1.93 1.37
M_002610 5163 Pyruvate dehydrogenase kinase, isozyme 1 1.91 1.27
M_021949 492 ATPase, Ca transporting, plasma membrane 3 1.9 1.21
08839 5329 Plasminogen activator, urokinase receptor 1.87 1.38
31933 2213 Fc fragment of IgG, low-affinity IIb, receptor (CD32) 1.87 1.37
W242432 359948 Interferon regulatory factor 2 binding protein 2 1.87 1.25
C005830 8416 Annexin A9 1.87 1.24
I347128 3476 Immunoglobulin (CD79A) binding protein 1 1.72 1.3
I870617 3732 CD82 antigen 1.68 1.25
M_003798 8727 Catenin (cadherin-associated protein) -like 1 1.68 1.25
L552534 960 CD44 antigen (homing function) 1.65 1.23
F455755 10018 BCL2-like 11 (apoptosis facilitator) 1.57 1.2
36501 6672 Nuclear antigen Sp100 1.56 1.2
F015452 8837 CASP8 and FADD-like apoptosis regulator 1.55 1.23
M_005526 3297 Heat shock transcription factor 1 1.55 1.22
C000251 2932 Glycogen synthase kinase 3 1.52 1.29
M_001861 1327 Cytochrome c oxidase subunit IV isoform 1 1.48 1.2
or a complete list, please refer to the Web site referenced in the text.
C, Fold change; LCB, lower confidence bound; ATPase, adenosine triphosphatase; BCL2, B-cell CLL/Lymphoma 2; CASP8, casapase-8; FADD, FAS-
ssociated death domain.
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Ramlawi et al Cardiopulmonary Support and PhysiologyABLE E4. Selected genes exhibiting significant downregulation at 6 hours postoperatively compared with those
reoperatively uniquely in patients without neurocognitive deficit
ccession Gene ID Gene FC LCB
C038712 57194 ATPase, class V, type 10A 15.23 1.88
M_145275 147700 Kinesin light chain 3 5.4 1.75
M_003837 8789 Fructose-1,6-bisphosphatase 2 4.73 1.68
M_002862 5834 Phosphorylase, glycogen; brain 3.58 1.71
E221674 152404 Immunoglobulin superfamily, member 11 2.72 1.34
I394679 43849 Kallikrein 12 2.51 1.34
25915 1191 Clusterin (complement lysis inhibitor) 2.46 1.59
M_016140 51673 Brain-specific protein 2.37 1.53
W057540 1636 Angiotensin 1–converting enzyme (peptidyl-dipeptidase A) 1 2.36 1.44
K098058 6300 Mitogen-activated protein kinase 12 2.3 1.54
90777 8828 Neuropilin 2 2.24 1.23
F416922 26027 Acyl-CoA thioesterase 11 2.21 1.43
L035661 84532 Acyl-CoA synthetase short-chain family member 1 2.17 1.31
I457620 1002 Cadherin 4, type 1, R-cadherin (retinal) 2.13 1.32
M_153042 221656 Amino oxidase (flavin-containing) domain 1 2.07 1.5
46752 54211 Oxidative stress–induced like 2.04 1.37
A306222 23028 Amine oxidase (flavin-containing) domain 2 2.03 1.46
U148326 54756 Interleukin 17 receptor D 2.02 1.47
C030972 9970 Nuclear receptor subfamily 1, group 1, member 3 2.02 1.23
B045831 63970 p53-regulated apoptosis-inducing protein 1 1.92 1.45
F009664 154754 Protease, serine, 1 (trypsin 1) 1.92 1.31
F196320 84818 Interleukin 17 receptor C 1.79 1.27
M_018725 55540 Interleukin 17 receptor B 1.75 1.37
M_000586 3558 Interleukin 2 1.73 1.2
F497548 131450 CD200 receptor 1 1.54 1.26
I885128 220296 Hepatocyte cell adhesion molecule 1.51 1.2
W296309 926 CD8 antigen,  polypeptide 1 (p37) 1.5 1.23
M_000277 5053 Phenylalanine hydroxylase 1.48 1.22
or a complete list, please refer to the Web site referenced in the text.
C, Fold change; LCB, lower confidence bound; ATPase, adenosine triphosphatase; Acyl-CoA, acyl-coenzyme A.
The Journal of Thoracic and Cardiovascular Surgery ● Volume 134, Number 4 1005.e4
CS
P
